DB:RV41

Stock Analysis Report

Executive Summary

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States.


Snowflake Analysis

Flawless balance sheet with moderate growth potential.

Share Price & News

How has Fennec Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RV41's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-19.7%

RV41

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

1.7%

RV41

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: RV41 exceeded the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: RV41 exceeded the German Market which returned 6.1% over the past year.


Shareholder returns

RV41IndustryMarket
7 Day-19.7%-4.1%-5.7%
30 Day13.0%-8.2%-5.7%
90 Day18.4%-2.0%-3.6%
1 Year1.7%1.7%4.0%3.7%9.3%6.1%
3 Year156.2%156.2%38.2%36.7%8.9%-0.7%
5 Year190.1%190.1%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Fennec Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Fennec Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

11.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RV41's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RV41's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RV41 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: RV41 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RV41's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RV41 is overvalued based on its PB Ratio (11.9x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Fennec Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

43.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RV41 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: RV41 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RV41's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if RV41's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if RV41's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RV41's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Fennec Pharmaceuticals performed over the past 5 years?

-52.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RV41 is currently unprofitable.

Growing Profit Margin: RV41 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RV41 is unprofitable, and losses have increased over the past 5 years at a rate of -52.9% per year.

Accelerating Growth: Unable to compare RV41's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RV41 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: RV41 has a negative Return on Equity (-107.58%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Fennec Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: RV41's short term assets ($13.9M) exceed its short term liabilities ($2.3M).

Long Term Liabilities: RV41 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: RV41 is debt free.

Reducing Debt: RV41 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: RV41 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if RV41's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RV41 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RV41 has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -34.7% each year.


Next Steps

Dividend

What is Fennec Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate RV41's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RV41's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RV41's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RV41's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RV41's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Rosty Raykov (43yo)

10.6yrs

Tenure

US$1,477,136

Compensation

Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of Fennec Pharmaceuticals Inc. (alternate name Adherex Technologies Inc) since July 2009 and serves as its President. Mr. Ray ...


CEO Compensation Analysis

Compensation vs Market: Rosty's total compensation ($USD1.48M) is above average for companies of similar size in the German market ($USD415.76K).

Compensation vs Earnings: Rosty's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Rostislav Raykov
CEO & Director10.6yrsUS$1.48m0.29% $370.8k
Robert Andrade
Chief Financial Officer4.3yrsUS$863.77k0.086% $109.4k
Shubh Goel
Chief Commercial Officer0.4yrsUS$1.23mno data
Mark Gowland
Controller4.3yrsno datano data
Lei Fang
President of Pharstat Inc0yrsno datano data
Anne McKay
Regulatory Consultant9.8yrsno datano data
Alexander Smith
Consultant0yrsno datano data

4.3yrs

Average Tenure

44.5yo

Average Age

Experienced Management: RV41's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rostislav Raykov
CEO & Director10.6yrsUS$1.48m0.29% $370.8k
Chris Rallis
Independent Director8.5yrsUS$126.65kno data
Khalid Islam
Independent Chairman of the Board4.2yrsUS$190.19kno data
Jodi Cook
Independent Director0.4yrsUS$112.43kno data
Adrian Haigh
Independent Director5.8yrsUS$124.15kno data
Marco Brughera
Independent Director3.5yrsUS$124.15kno data

5.0yrs

Average Tenure

62yo

Average Age

Experienced Board: RV41's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.


Top Shareholders

Company Information

Fennec Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fennec Pharmaceuticals Inc.
  • Ticker: RV41
  • Exchange: DB
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$138.873m
  • Listing Market Cap: US$127.652m
  • Shares outstanding: 19.90m
  • Website: https://www.fennecpharma.com

Number of Employees


Location

  • Fennec Pharmaceuticals Inc.
  • 68 TW Alexander Drive
  • PO Box 13628
  • Research Triangle Park
  • North Carolina
  • 27709
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RV41BST (Boerse-Stuttgart)COM NPVDEEURNo data
FRXTSX (The Toronto Stock Exchange)YesCommon SharesCACADJun 2001
RV41DB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2001
FENCNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJun 2001

Biography

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/26 20:38
End of Day Share Price2020/02/26 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.